Precure, LLC selects Helix as multi-omics lab and AI tools provider

Helix to generate clinical whole genome sequencing and multi-omics data from one million biospecimens, advancing precision medicine as the standard of care

ROCHESTER, Minn. and SAN MATEO, Calif., Sept. 21, 2026 /PRNewswire/ -- Precure, LLC today announced the selection of Helix as its multi-omic laboratory and AI tools provider supporting plans to generate comprehensive molecular data from approximately one million biospecimens and accelerate the integration of molecular insights into routine clinical care at Mayo Clinic and across health systems more broadly.

Less than a week ago, Mayo Clinic announced the launch of Precure, LLC, with founding partner Thermo Fisher Scientific, to help transform how the life sciences community understands the biological changes that occur as disease develops before symptoms occur. Precure, LLC brings together clinical expertise, de-identified longitudinal health information and population-scale molecular data to accelerate the development of new approaches to care.

Helix will provide both advanced AI tools for delivery of genomics into the clinic and biomarker driven research, and population scale multi-omic capability that encompasses clinical whole genome sequencing (WGS) and research grade proteome sequencing. Linked with longitudinal clinical information and high performance compute infrastructure, the objective is to create new opportunities for prevention, diagnosis and treatment.

"Our goal is to generate genomic information that can help inform patient care while creating a powerful resource for discovery," said Aaron Mangold, M.D., chief medical officer, Precure, LLC. "We are working to make clinical whole genome sequencing and multi-omics a foundation of care, helping us detect disease sooner and act earlier."

Building on prior work which utilized Helix's Exome+^® sequencing technology, Precure, LLC extends that collaboration by leveraging Helix's experience providing workflow orchestration, (CLIA/CAP) genomic sequencing, data infrastructure, and AI tools to its health system partners. Precure, LLC and Helix have selected Ultima Genomics' UG200™ Ultra Sequencing Platform as part of the program's large-scale multi-omics initiative. Helix will use a fleet of Ultima's next-generation platforms to generate high-quality genomic data for WGS and read-out for proteomics at scale.

"The genome is becoming an enduring patient resource, providing a precision baseline for a lifetime of care," said James Lu, M.D., Ph.D., CEO of Helix. "Helix brings together the laboratory and data capabilities to make this possible at scale."

Mayo Clinic's involvement in Precure, LLC is intended to advance its nonprofit mission. Any financial returns to Mayo Clinic would be reinvested in its mission of patient care, research and education. Visit mayo.edu/research/precure for more information.

About Precure, LLC
Precure, LLC is a Mayo Clinic-controlled company established to generate and responsibly integrate population-scale molecular data with longitudinal clinical information. Precure, LLC creates the infrastructure and scale needed to enable external collaborations, disease-focused discovery and the development of new diagnostics, therapeutics and other healthcare solutions. It complements Mayo Clinic's investigator-led research and clinical translation activities.

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to innovation in clinical practice, education and research, and providing compassion, expertise and answers to everyone who needs healing. Visit the Mayo Clinic News Network for additional Mayo Clinic news. 

About Helix
Helix is an enterprise genomics company connecting clinical care and discovery. Its platform brings together clinical sequencing, integration of genomic information into healthcare, and research tools built on linked genomic and longitudinal clinical data. Through its health system partnerships, the Helix Research Network and GenoSphere, Helix helps healthcare and life sciences organizations apply genomics to patient care and the development of new diagnostics and treatments. Learn more at www.helix.com.

Media contacts
Mayo Clinic: Tom Millikin, newsbureau@mayo.org
Helix: Caty Reid, helix@highwirepr.com

SOURCE Helix